Annotation Detail

Information
Associated Genes
CDKN2A
Associated Variants
CDKN2A LOSS ( ENST00000579755.2 )
CDKN2A LOSS ( ENST00000579755.2 )
Associated Disease
ovarian cancer
Source Database
CIViC Evidence
Description
Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1377
Gene URL
https://civic.genome.wustl.edu/links/genes/14
Variant URL
https://civic.genome.wustl.edu/links/variants/554
Rating
3
Evidence Type
Predictive
Disease
Ovarian Cancer
Evidence Direction
Supports
Drug
Palbociclib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
21278246
Drugs
Drug NameSensitivitySupported
PalbociclibSensitivitytrue